Farmas USA

SNTA, pre 200 shares, 7,00$

Vertigo!!! :) con +45% a dia de hoy. hasta dónde (en precio o tiempo)???

Lo cierto es que el anuncio de la nueva tecnologia de SNTA ha pillado por sorpresa al mercado ya que no es muy frecuente que una farma ( de esta capitalizacion), desarrolle en secreto al margen de su pipeline oficial.
Supongo que se requiere tiempo para que los analistas "analicen" y valoren.

Yo quiero ver con que fuerza rompe los 7,1x y si nos lleva en un tiron semanal al rango de los 8$.
Ahi soltare.

Yo veo los 10 antes de diciembre. Tiene catalizadores a final de año.

SNTA pre 7,50!

HEB

Noticias buenas. N otengo tiempo de leerlas. LAs copio

Natural Human Interferon (a-n3) is Active Against Both Wild-type and Oseltamivir Resistant Avian-Origin Influenza A (H7N9) Virus

… Data presented at 53rd annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado September 9-13, 2013

PHILADELPHIA, PA, September 12, 2013: Hemispherx Biopharma (NYSE MKT: HEB) announced that at the 53rd annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado during September 9-13, 2013, that William Mitchell, MD, Ph.D., Professor Pathology, Microbiology, and Immunology, Vanderbilt University, presented the results of a study of Hemispherx product, Alferon N Injection®, the only multi-species, natural interferon approved in the U.S. for the treatment of human refractory HPV genital warts, against wild type and oseltamivir (Tamiflu)-resistant H7N9 influenza virus.

The increasing prevalence of oseltamivir-resistant Influenza A Virus, particularly against H7N9, has been widely reported and is due in large part to the fact that just a single-step mutation in this genetically unstable virus makes it resistant to oseltamivir. Dr. Mitchell, who is member of the Board of Directors of Hemispherx, discussed new experiments on the inhibition of Tamiflu®-resistant H7N9 virus by Alferon N Injection®.

These experiments were conducted at Kansas State University by Professor Juergen Richt, DVM, Ph.D., Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Regents Distinguished Professor of Veterinary Medicine at Kansas State University and an Eminent Scholar of Kansas Bioscience Association (KBA) along with his staff.
Dr. Mitchell described the results with Alferon®, including in-vitro experiments directed against inhibiting the Tamiflu®-resistant H7N9 highly pathogenic influenza strain. Tamiflu® (oseltamivir) and Alferon® were tested in A549 cells for antiviral activity in vitro against the wild-type (wt) human A(H7N9) isolate A/Anhui/1/2013 (wt Anhui 1) and a patient isolate (A/Shanghai/1/2013 (NA-292K; Shanghai 1-NA292K)) with resistance to oseltamivir.

The wt Anhui 1 was sensitive to both Tamiflu® and Alferon®. The Shanghai 1-NA292K virus was resistant to Tamiflu® treatment but was sensitive to Alferon® when tested in A549 cells. These initial results showed that:

• Tamiflu® and Alferon® have a significant inhibitory effect on the wild-type A(H7N9) virus. Alferon® but not Tamiflu® had a significant inhibitory effect on oseltamivir-resistant neuraminidase mutant Shanghai 1-NA292K.

• Alferon® is similar to oseltamivir in reduction of titers from wt A(H7N9) isolates following 48 hours exposure to each drug

• Alferon® appears to be highly effective as an inhibitor the A(H7N9) strain which demonstrates marked resistance to oseltamivir (Tamiflu®)

• Tamiflu®-resistant H7N9 viruses are associated with poor clinical outcomes. The potential for pandemic spread is dependent on the acquisition of additional mutations in the viral hemagglutinin gene allowing efficient human to human spread. Alferon offers an evidence based new therapeutic strategy to mitigate the health hazards associated with the potential pandemic spread of neuraminidase inhibitor-resistant human influenza viruses.

emispherx Announces Initial Test Results in Biosecurity/Biodefense Arena

PHILADELPHIA, PA, September 12, 2013: Chairman and CEO, William A. Carter, M.D. of Hemispherx Biopharma (NYSE MKT: HEB) announced at the Rodman and Renshaw Conference in New York City, NY on September 9, 2013, a major new initiative in the BioSecurity field involving both Alferon N Injection® and Ampligen®. Alferon N Injection® is a multi-species, natural interferon; the only natural interferon approved for sale in the U.S. Ampligen® is a dsRNA experimental therapeutic that acts as a TLR 3 activator.

Dr. Carter highlighted the broad anti-viral effect of both drugs/biologics. The Company’s strategy includes plans to undertake major programs in the biosecurity field, specifically with respect to the potential prevention or treatment of pandemic flu virus, H7N9, MERS (Middle East Respiratory Syndrome) and alpha viruses such as VEE (Venezuelan Equine Encephalomyelitis). With all three classes of viruses, researchers have now confirmed significant bioactivity with Ampligen® or Alferon N Injection®, or both, in either in vitro and/or in vivo non-human studies. Alferon N Injection® has been found to be highly active against SARS virus (a close relative of MERS) by the Singapore Genome Institute in laboratory studies.

Dr. Carter highlighted the work that was recently presented at the Options for the Control of Influenza VIII Conference in Cape Town, South Africa, September, 5-10, 2013 by Professor Dr. Juergen A. Richt, DVM, Ph.D., Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD). The Cape Town presentations described the results with Alferon®, including in-vitro experiments directed against inhibiting the Tamiflu®-resistant H7N9 pandemic influenza strain. Tamiflu® (oseltamivir) and Alferon® were tested in A549 cells for antiviral activity in vitro against the wild-type (wt) human A(H7N9) isolate A/Anhui/1/2013 (wt Anhui 1) and a patient isolate (A/Shanghai/1/2013 (NA-292K; Shanghai 1-NA292K) with resistance to oseltamivir. The wt Anhui 1 was sensitive to both Tamiflu® and Alferon®. The Shanghai 1-NA292K virus was resistant to Tamiflu® treatment but was sensitive to Alferon® when tested in A549 cells.
The results of the recent Kansas State University experiments, coupled with Dr. Richt’s work on reassortment and other published studies, sets the stage for evaluating the possibility that mutational changes and reassortment could be prevented in animals by the use of type I interferon and/or a type I interferon inducer. These laboratory results to date suggest that Alferon® may be a promising candidate to treat the virulent and potentially lethal Tamiflu®-resistant H7N9 virus in animals and humans. Moreover, previous research suggests that Alferon® may be active against a range of viruses existing in animal populations even in the low dose oral (LDO) formulation referred to as Alferon® LDO.

Dr. Carter highlighted the collaborations between Hemispherx and leading institutions in the BioSecurity field on both the Alferon® and Ampligen® platforms, such as U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Kansas State University, College of Veterinary Medicine; Institute for Antiviral Research, Utah State University; Center of Biodefense and Emerging Disease, University of Texas Medical Branch; Preclinical Drug Development, Lovelace Respiratory Research Institute; Hokkaido University, Japan OIE World Reference Laboratory, Hokkaido Department of Disease Control, School of Veterinary Medicine, Research Center for Zoonosis Control; and University of Alabama Clinical Research Unit.

In April of 2012, Hemispherx announced that Ampligen®, an experimental immunotherapeutic, has been nasally administered in conjunction with FluMist® to healthy human volunteers in a study being conducted at the University of Alabama at Birmingham under the auspices of Dr. Paul Goepfert, Associate Professor of Medicine in the Division of Infectious Diseases and Director of the Alabama Vaccine Research Clinic. The objective is to determine the extent to which Ampligen® may mobilize potential protections against pandemic influenza when used in conjunction with a seasonal flu vaccine; even against mutated strains of flu virus.

Studies have now progressed at the University of Alabama (http://www.hemispherx.net/content/investor/default.asp?goto=732), and suggest that Ampligen®, given intranasally in healthy human volunteers in combination with FluMist® (a commercially available seasonal flu vaccine also given intranasally), may result in elaboration of potentially protective antibody against pandemic influenza strains.

About Hemispherx Biopharma

emispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
….Presentation at Options for the Control of Influenza VIII Conference in Cape Town, South Africa 5-10 September, 2013

PHILADELPHIA, PA, September 12, 2013: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) announced that at the Options for the Control of Influenza VIII Conference in Cape Town, South Africa held 5-10 September, 2013, that a scientific advisor to Hemispherx, Professor Dr. Juergen A. Richt, DVM, Ph.D., Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Regents Distinguished Professor at Kansas State University, and an Eminent Scholar of Kansas Bioscience Association (KBA), described his experiments in human lung cells evidencing that Alferon N Injection®, the only multi-species, natural interferon approved in the U.S. for the treatment of human refractory HPV genital warts, is biologically active, in low doses, against various classes of viruses occurring naturally in animals and humans.

The increasing prevalence of oseltamivir-resistant Influenza A viruses (IAVs), particularly H7N9, has been widely reported and is due in large part to the fact that just a single-step mutation in the neuraminidase (NA) gene of this genetically unstable virus makes it resistant to oseltamivir (Tamiflu®). Dr. Richt reported on influenza genome instability "Viral reassortment and transmission after co-infection of pigs with classical H1N1 and triple-reassortant H3N2 swine influenza viruses” in 2010 in the peer-reviewed Journal of General Virology, an international journal.

The results of the recent Kansas State University experiments, coupled with Dr. Richt’s work on reassortment and other published studies, set the stage for evaluating the possibility that mutational changes and reassortment could be prevented in animals by the use of type I interferon and/or a type I interferon inducer.

Professor Richt’s diverse experimental program, sponsored in part by the U.S. Department of Homeland Security, National Institutes of Health, European Union, U.S. Department of Agriculture, and private entities, focuses on molecular mechanisms and pathogenesis of emerging pathogens in livestock populations as a critical first step in promoting and causing human disease, including various zoonotic viruses such as highly pathogenic influenza viruses, H7N9 or H5N1(i.e. zoonotic agents).

New data regarding the genesis of pandemic flu, recently summarized by researchers at the National Institutes of Health (NIH) in "Pandemic Influenza Viruses — Hoping for the Road Not Taken”, David M. Morens, M.D., Jeffery K. Taubenberger, M.D., Ph.D., and Anthony S. Fauci, M.D. N Engl J Med 2013; 368:2345-2348 June 20, 2013DOI: 10.1056/NEJMp1307009, identifies viral reassortment events occurring in animals as potential major contributors to the eventual jump into humans (cross-species transmission). Professor Richt is recognized as an expert on zoonotic agents (i.e. influenza, Prions, Rift Valley Fever, etc.) and has published extensively on the monitoring of the mutations and the basic events leading to cross-species transmission and the opportunities to adapt to its new human host with the potential to cause a pandemic.

Professor Richt described the results with Alferon®, including in-vitro experiments directed against inhibiting the Tamiflu®-resistant H7N9 pandemic influenza strain. Tamiflu® (oseltamivir) and Alferon® were tested in A549 cells for antiviral activity in vitro against the wild-type (wt) human A(H7N9) isolate A/Anhui/1/2013 (wt Anhui 1) and a patient isolate (A/Shanghai/1/2013 (NA-292K; Shanghai 1-NA292K)) with resistance to oseltamivir. The wt Anhui 1 was sensitive to both Tamiflu® and Alferon®. The Shanghai 1-NA292K virus was resistant to Tamiflu® treatment but was sensitive to Alferon® when tested in A549 cells. These initial results showed that:
• Tamiflu® and Alferon® have a significant inhibitory effect on the wild-type A(H7N9) virus. Alferon® but not Tamiflu® had a significant inhibitory effect on oseltamivir-resistant neuraminidase mutant Shanghai 1-NA292K.
• Alferon® is similar to oseltamivir in reduction of titers from wt A(H7N9) isolates following 48 hours exposure to each drug
• Alferon® appears to be highly effective as an inhibitor of the A(H7N9) strain which demonstrates marked resistance to oseltamivir (Tamiflu®)
• These results suggest new therapeutic strategies to mitigate the health hazards associated with the infection and the potential pandemic spread of neuraminidase-resistant human influenza viruses.

SNTA

Fast Track!!!!!!

http://www.4-traders.com/SYNTA-PHARMACEUTICALS-COR-42507/news/Synta-Pharmaceuticals-Corp--Synta-Announces-Fast-Track-Designation-Granted-for-Ganetespib-in-Non-S-17261748/

$$$$$$$$$$

Coño, eso es cojonudo, Framus!!!!!!
A esta hora, sube un 8%, con 36k títulos...
En mi cartera, a esta hora, con plus del 25%....
A ver si me cambio de casa con las plus de SNTA...jajajajjaja
Ole, ole, ole....

Por cierto, las MACK en pre, subiendo un 3%, aunque con una miseria de títulos...

News CBRX...

Columbia Laboratories Inc. (CBRX) reported acquiring privately-held Molecular Profiles Ltd., a cash-flow positive, U.K.-based pharmaceutical development services company, for about $25.0 million, including $16.7 million cash and 1.05 million shares of Columbia, representing ten to eleven times Molecular Profiles' projected EBITDA for its fiscal year to July 31, 2014. (Sep 12, 2013)

Si no recuerdo mal, está empresa, que la seguí durante un tiempo, hasta que me pego algún arreón en decisiones de la FDA, investigaba sobre la "Viagra" femenina, o algo así....

Un saludo